La chaîne d'options affiche les données clés des options sur actions de Intellia Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Intellia Therapeutics..

Intellia Therapeutics (NASDAQ:NTLA) Stock, Chaîne d'Options

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

MultiPlan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) reported quarterly losses of $(24.25) per share. This is a 1527.52 percent decrease over losses of $(1.49) per share from the same period last year. The company reported quarterly sales of $230.50 million which missed the analyst consensus estimate of $233.67 million by 1.36 percent. This is a 5.07 percent decrease over sales of $242.80 million the same period last year.

Earnings

News

MPLN

MultiPlan Q3 2024 GAAP EPS $(24.25) Down From $(1.49) YoY, Sales $230.50M Miss $233.67M Estimate

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="4" rowspan="1">Financial Outlook</td>
</tr>
<tr>
<td colspan="4" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Dollars in millions, unless noted</td>
<td colspan="1" rowspan="1">4Q'24E</td>
<td colspan="1" rowspan="1">
Current
Full Year 2024E
</td>
<td colspan="1" rowspan="1">
Prior
Full Year 2024E
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales</td>
<td colspan="1" rowspan="1">~$3,070</td>
<td colspan="1" rowspan="1">~$12,365</td>
<td colspan="1" rowspan="1">$12,400 - $12,500</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating EBITDA(2)</td>
<td colspan="1" rowspan="1">~$790</td>
<td colspan="1" rowspan="1">~$3,125</td>
<td colspan="1" rowspan="1">$3,060 - $3,110</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS(2)</td>
<td colspan="1" rowspan="1">~$0.98</td>
<td colspan="1" rowspan="1">~$3.90</td>
<td colspan="1" rowspan="1">$3.70 - $3.80</td>
</tr>
</tbody>
</table>
</figure>

Guidance

DuPont Sees Q4 Adj EPS $0.98 vs $0.98 Est; Sees Sales $3.070B vs $3.14B Est

Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) reported quarterly earnings of $2.50 per share which beat the analyst consensus estimate of $2.39 by 4.6 percent. The company reported quarterly sales of $1.484 billion which beat the analyst consensus estimate of $1.475 billion by 0.60 percent. This is a 5.32 percent increase over sales of $1.409 billion the same period last year.

Earnings Beats

Gartner Q3 2024 Adj. EPS $2.50 Beats $2.39 Estimate, Sales $1.484B Beat $1.475B Estimate

SQNS

Sequans Communications Q3 2024 Adj. EPADS $2.91 Beats $(0.38) Estimate, Sales $10.080M Beat $4.800M Estimate

Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $1.17 by 4.27 percent. The company reported quarterly sales of $3.17 billion which missed the analyst consensus estimate of $3.24 billion by 1.90 percent. This is a 0.38 percent increase over sales of $3.16 billion the same period last year.

HSIC

Henry Schein Q3 2024 Adj EPS $1.22 Beats $1.17 Estimate, Sales $3.17B Miss $3.24B Estimate

Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) reported quarterly sales of $3.852 billion which missed the analyst consensus estimate of $4.060 billion by 5.13 percent. This is a 1.16 percent decrease over sales of $3.897 billion the same period last year.

Earnings Misses

TRGP

Targa Resources Q3 Sales $3.852B Miss $4.060B Estimate

Stifel analyst Paul Matteis upgrades Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) from Hold to Buy and raises the price target from $25 to $36.

Upgrades

Price Target

Analyst Ratings

ALKS

Stifel Upgrades Alkermes to Buy, Raises Price Target to $36

Vestas Wind Systems (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWDRY#OTC">VWDRY</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.09 by 44.44 percent. The company reported quarterly sales of $5.690 billion which beat the analyst consensus estimate of $5.512 billion by 3.23 percent. This is a 20.09 percent increase over sales of $4.738 billion the same period last year.

VWDRY

Vestas Wind Systems Q3 2024 GAAP EPS $0.05 Misses $0.09 Estimate, Sales $5.690B Beat $5.512B Estimate

Louisiana-Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $0.88 by 38.64 percent. This is a 24.69 percent decrease over earnings of $1.62 per share from the same period last year. The company reported quarterly sales of $722.00 million which beat the analyst consensus estimate of $680.23 million by 6.14 percent. This is a 0.82 percent decrease over sales of $728.00 million the same period last year.

Louisiana-Pacific Q3 2024 Adj EPS $1.22 Beats $0.88 Estimate, Sales $722.00M Beat $680.23M Estimate

DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $1.03 by 14.56 percent. This is a 28.26 percent increase over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $3.192 billion which missed the analyst consensus estimate of $3.204 billion by 0.38 percent. This is a 4.38 percent increase over sales of $3.058 billion the same period last year.

DuPont Q3 2024 Adj. EPS $1.18 Beats $1.03 Estimate, Sales $3.192B Miss $3.204B Estimate

B. Riley Securities analyst Jeff Van Sinderen initiates coverage on MSA Safety (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSA#NYSE">MSA</a>) with a Buy rating and announces Price Target of $200.

Initiation

B. Riley Securities Initiates Coverage On MSA Safety with Buy Rating, Announces Price Target of $200

Anglo American (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAUKF#OTC">AAUKF</a>) has agreed to sell its 33.3% stake in the Jellinbah Group to Zashvin for $1.1 billion. Per the plan laid out <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/38826363/anglo-american-expedites-plan-to-divest-de-beers-other-assets-after-rebuffing-bhp-takeover-bid" rel="noreferrer noopener">earlier this year</a>, the company is focusing on <a target="_blank" href="https://www.benzinga.com/topic/copper" rel="noreferrer noopener">copper</a>, iron ore, and crop nutrients.
The joint venture holds a 70% interest in two major metallurgical coal mines in Queensland: Jellinbah East and Lake Vermont. Anglo did not operate these mines nor market their output.
"We are making excellent progress with our simplification of Anglo American to create an exciting and differentiated investment proposition focused on our world-class copper, premium iron ore, and crop nutrients assets &#8211; all future-enabling products," <a target="_blank" href="https://www.angloamerican.com/media/press-releases/2024/04-11-2024" rel="noreferrer noopener">said</a> CEO Duncan Wanblad.
Despite its unpopular status due to environmental concerns, coal remains an important commodity. A recent <a target="_blank" href="https://www.benzinga.com/news/24/11/41710410/australian-breakthrough-extends-use-for-coal-powered-plants-helps-shift-to-renewables" rel="noreferrer noopener">Australian achievement</a> in shutting down and restarting a power plant shows that its decline could be much more gradual than anticipated.
Still, Anglo American is set on divesting its remaining coal assets, aiming to net between $5b and $6b. Talks are underway with potential buyers, including Peabody (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>), Yancoal (OTCPK: YACAF), and Glencore (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GLNCY#OTC">GLNCY</a>) &#8211; which has decided against <a target="_blank" href="https://www.benzinga.com/m-a/24/08/40216672/glencore-votes-against-spinning-off-coal-remains-open-to-more-acquisitions" rel="noreferrer noopener">spinning off its coal business</a>.
"This highly cash generative and much higher margin portfolio will offer greater resilience through cycles and the benefit of significant high-quality and well-sequenced growth options," Wanblad noted regarding the process.
Anglo American's broader restructuring efforts were announced earlier this year amidst an attempted takeover by BHP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>). Besides coal, the plan involved shedding even South African De Beers, the world's largest diamond producer.
However, challenges in the diamond market have made a sale less feasible, with Anglo preferring to wait for market recovery to optimize value from its "crown jewel." A complicated situation with South African assets is often quoted as one of the biggest hurdles in BHP's <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/39068033/time-runs-out-for-bhp-deal-49-billion-acquisition-of-anglo-american-proves-too-complex-to-solve" rel="noreferrer noopener">failed bid</a>.
Although a recent comment from BHP's chairman signaled that both parties have moved on, the miner quickly retraced that comment. The mandatory standstill on offers expires on November 29, with Anglo's market cap currently at approximately $42 billion—$47 billion below BHP's final $49b bid in May.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/11/41722178/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan" target="_blank" rel="noreferrer noopener">If Trump And Republicans Sweep, Dollar May Climb 7% — But Harris Win Could Bring 5% Drop, Says JPMorgan</a></li>
</ul>
Photo via Company

Large Cap

Commodities

Asset Sales

AAUKF

GLNCY

YACAF

Anglo American Offloads $1.1 Billion Coal Stake, Proceeds With Restructuring

Dr Reddy's Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $84.03 by 99.79 percent. This is a 14.29 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $957.00 million which missed the analyst consensus estimate of $76.49 billion by 98.75 percent. This is a 16.57 percent increase over sales of $821.00 million the same period last year.

Dr Reddy's Laboratories Q2 2025 GAAP EPS $0.18 Compared To $0.21 YoY, Sales $957.00M Compared To $821M YoY

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) with a Overweight rating and announces Price Target of $75.

Piper Sandler Initiates Coverage On Upstream Bio with Overweight Rating, Announces Price Target of $75

Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) expanded its multi-year partnership with Telia Company to advance Telia&#8217;s modernization and transformation of telecom and cloud infrastructure <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41737175/broadcom-and-telia-announce-expanded-partnership-to-further-transform-telco-and-cloud-infrastructu" rel="noreferrer noopener">using VMware&#8217;s product portfolio</a>.
The expanded use of VMware&#8217;s cloud-native architecture will advance Telia&#8217;s automation efforts across network workloads and extend its cloud-native capabilities for key assets.
Krish Prasad, SVP and general manager, VMware Cloud Foundation Division, Broadcom, said, &#8220;We are delighted to enable Telia to continue serving its customers with this VMware software-based platform that includes the needed network and infrastructure orchestration, automation and scale.&#8221;
In addition, Broadcom disclosed significant enhancements to its VeloCloud product line and introduced a new partner program aimed at helping enterprises better support AI and non-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41737271/broadcom-unveils-velorain-an-industry-first-for-robust-ai-networking-beyond-the-data-center" rel="noreferrer noopener">AI workloads and enhance connectivity</a>.
Broadcom&#8217;s latest advancements include the launch of VeloRAIN, an AI/ML-powered architecture designed to boost the performance and security of distributed AI workloads.
It also introduced the high-capacity VeloCloud Edge 4100 and 5100 appliances, which support up to 100Gbps for large enterprises. Additionally, the new Titan Partner Program will help VeloCloud Managed Service Providers grow as enterprise AI adoption accelerates.
Sanjay Uppal, vice president and general manager, VeloCloud Division, Broadcom, stated, &#8220;By harnessing the advanced capabilities of VeloRAIN, AI workloads from distributed inferencing and agentic peer-to-peer applications to upstream heavy RAG transactions will see improved application-based QoE and security across all endpoints of the enterprise.&#8221;
Apart from this, at VMware Explore 2024 in Barcelona, the company disclosed expanded VMware Cloud Foundation (VCF) Advanced Services, new ecosystem <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41737281/vmware-cloud-foundation-delivers-a-private-cloud-platform-to-accelerate-customers-ai-sovereignty-a" rel="noreferrer noopener">partnerships, and modernization programs</a>.
These initiatives aim to accelerate generative AI application development, enhance cybersecurity, and support sovereign cloud adoption.
Krish Prasad, senior vice president and general manager, VCF Division at Broadcom, commented, &#8220;Through a private cloud platform and portfolio of Advanced Services that are ubiquitous, flexible and secure, we are unlocking the promise of AI in the enterprise, delivering new levels of organizational resilience, and supporting the privacy and digital sovereignty demands of customers around the world.&#8221;
Investors can gain exposure to the stock via Direxion Daily AVGO Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVL#NASDAQ">AVL</a>) &nbsp;and&nbsp;Columbia Semiconductor and Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMI#NYSE">SEMI</a>).
Price Action: AVGO shares are up 0.49% at $169.38 premarket at the last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41609022/openai-chooses-broadcom-for-ai-interface-chip-development" target="_blank" rel="noreferrer noopener">OpenAI Chooses Broadcom For AI Interface Chip Development</a></li>
</ul>

Equities

Contracts

AVGO

SEMI

Broadcom Powers Telia's Modernization with VMware, Launches AI-Driven VeloRAIN & More

Piper Sandler analyst Edward Tenthoff initiates coverage on Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) with a Overweight rating and announces Price Target of $18.

CAMP

Piper Sandler Initiates Coverage On Camp4 Therapeutics with Overweight Rating, Announces Price Target of $18

BitFuFu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) reported quarterly losses of $(0.03) per share. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $90.34 million in sales this quarter. This is a 47.57 percent increase over sales of $61.22 million the same period last year.

FUFU

BitFuFu Q3 EPS $(0.03) Down From $(0.02) YoY, Sales $90.34M Up From $61.22M YoY

Shares of Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">above consensus estimates</a>.
Revenue increased 5% year over year to $3.07 billion, beating the consensus of $3.05 billion. Adjusted EPS of 77 cents surpassed the street view of 68 cents.
Palantir Technologies shares rose 12.9% to $46.75 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Simpple Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) gained 69.5% to $2.00 in pre-market trading after jumping around 269% on Monday.</li>
<li>Bionomics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) rose 67.6% to $0.3219 in pre-market trading. Bionomics received milestone payment of AUS$1 million from Carina Biotech for BNC101 partnered legacy oncology program.</li>
<li>Avalon GloboCare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALBT#NASDAQ">ALBT</a>) shares surged 42.4% to $3.19 in pre-market trading after dipping 24% on Monday.</li>
<li>QuinStreet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) climbed 29.8% to $26.22 in pre-market trading after the company posted upbeat quarterly results and raised its FY25 sales outlook.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) gained 26.1% to $87.83 in pre-market trading after the company announced better-than-expected quarterly results.</li>
<li>Zyversa Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares rose 15.3% to $2.10 in pre-market trading after falling 5% on Monday.</li>
<li>Vimeo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) gained 15.2% to $5.54 in pre-market trading after the company posted upbeat quarterly results.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 12.6% to $3.12 in pre-market trading.</li>
<li>Alarum Technologies Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) gained 16.6% to $14.39 in pre-market trading.</li>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 11.9% to $0.0225 in pre-market trading after the company announced update and extension of pending offer to exchange.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) shares tumbled 38.8% to $3.64 in pre-market trading following weak quarterly sales.</li>
<li>Verrica Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares fell 31.4% to $0.98 in pre-market trading after the company posted downbeat quarterly results.</li>
<li>Trio Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NYSE">TPET</a>) dipped 24.8% to $0.0960 in pre-market trading after the company announced a 1-for-20 reverse stock split.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares fell 19.4% to $2.10 in pre-market trading after the company reported weak third-quarter sales.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) declined 18% to $42.55 in pre-market trading following soft fourth-quarter guidance.</li>
<li>Nft Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MI#NYSE">MI</a>) shares dipped 16.1% to $7.50 in pre-market trading after gaining 9% on Monday.</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) fell 16.2% to $5.66 in pre-market trading after surging more than 40% on Monday.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) fell 15.8% to $103.89 in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and announced it intends to temporarily reduce its quarterly dividend.</li>
<li>Altice USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) fell 14.3% to $2.22 in pre-market trading after the company reported weak third-quarter financial results.</li>
<li>Tactile Systems Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) fell 10.3% to $13.55 in pre-market trading after the company posted weak quarterly sales and lowered FY24 sales forecast.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41735761/dow-tumbles-250-points-as-investors-brace-for-high-stakes-presidential-election-greed-index-enters-">Dow Tumbles 250 Points As Investors Brace For High-Stakes Presidential Election: Greed Index Enters &#8216;Fear&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALAB

ALAR

ALBT

ATUS

BNOX

ELAB

LSCC

NVTS

PLTR

QNST

SPPL

TCMD

TPET

VMEO

VRCA

VSTE

ZVSA

Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

SBSW

Sibanye Stillwater Q3 Adjusted EBITDA $184M, Up 9% Year-On-Year

Legal

NFLX

Reuters Reported France's PNF Financial Prosecutor Body Has Carried Out Searches Today At Netflix France, Amsterdam Offices, Citing Judicial Source

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NTLA stock, giving a Buy rating today. Mani Foroohar has given his Bu...

Intellia Therapeutics: Promising Phase 2 Results and Growth Potential Justify Buy Rating

Citi analyst David Lebowitz lowered the firm's price target on Intellia Therapeutics (NTLA) to $19 from $25 and keeps a Neutral rating on the share...

Intellia Therapeutics price target lowered to $19 from $25 at Citi

David Lebowitz, an analyst from Citi, maintained the Hold rating on Intellia Therapeutics (NTLA – Research Report). The associated price target is ...

Intellia Therapeutics' NTLA-2002: Hold Rating Amid Competitive Challenges and Safety Concerns

Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity

Intellia Therapeutics ( ($NTLA) ) has provided an announcement. Intellia Therapeutics has announced promising Phase 2 results for NTLA-2002, a CRIS...

Intellia Therapeutics Advances with Promising Phase 2 Results

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2024 Update

Warning: NTLA is at high risk of performing badly

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on NTLA stock, giving a Buy rating on October 25. Debanjana Chatterje...

Intellia Therapeutics: Positive Outlook and Buy Rating Amid Promising Data for ATTR-CM Treatment

Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story

ALNY

ARKB

ARKF

ARKG

ARKK

ARKQ

ARKW

ARKX

BCRX

BEAM

COIN

CRSP

DKNG

HOOD

IONS

NTLA

PATH

RBLX

REGN

ROKU

RXRX

SHOP

TKPHF

TSLA

Press Releases

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

Health Care

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Comments

Intellia Therapeutics

Intellia Therapeutics (NTLA) Options

Intellia Therapeutics (NASDAQ:NTLA) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL